Bio-Rad Laboratories Outperforms TREES in Financial Review

Comparison of two medical companies shows Bio-Rad Laboratories has stronger financials and analyst ratings

Published on Mar. 11, 2026

Got story updates? Submit your updates here. ›

Bio-Rad Laboratories (NYSE:BIO) and TREES (OTCMKTS:CANN) are both medical companies, but a comparison of the two reveals that Bio-Rad Laboratories has stronger financial performance, institutional ownership, and analyst ratings compared to TREES.

Why it matters

This analysis provides investors with a detailed look at the relative strengths and weaknesses of these two medical companies, which can help inform investment decisions in the healthcare sector.

The details

The comparison shows that Bio-Rad Laboratories has higher gross revenue, earnings per share, and valuation compared to TREES. Bio-Rad Laboratories also has significantly stronger institutional ownership at 65.2% versus 11.3% for TREES, indicating greater confidence from large investors. Additionally, Bio-Rad Laboratories has a higher consensus analyst rating and price target, suggesting it is viewed more favorably by the research community.

  • The financial data and analysis is current as of March 11, 2026.

The players

Bio-Rad Laboratories

A manufacturer and distributor of life science research and clinical diagnostic products, headquartered in Hercules, California.

TREES

A provider of products and services to the regulated cannabis industry, headquartered in Lakewood, Colorado.

Got photos? Submit your photos here. ›

The takeaway

This analysis highlights Bio-Rad Laboratories' stronger financial position and more favorable analyst ratings compared to its competitor TREES, providing investors with valuable insights to consider when evaluating opportunities in the medical technology sector.